Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Crescent Biopharma announced pipeline momentum for CR-001, its PD-1 x VEGF bispecific, with dose escalation complete in the global Phase 1/2 ASCEND trial and more than 125 patients dosed across the US, Europe and South Korea. Enrollment has begun in standard-of-care chemotherapy combination cohorts across first-line NSCLC, colorectal, biliary tract, gastric and endometrial cancers, with initial monotherapy data expected in Q1 2027 and combination data in mid-2027.
Key figures
- Drug Name
- CR-001
- Phase Of Trial
- Phase 1/2
- Combination data
- mid-2027 (Q2/Q3)
- Patients dosed ascend
- more than 125
- Potential phase 3 start
- early 2028
- Initial monotherapy data
- Q1 2027
- Sac tmt combination patients
- more than 700
- Expected portfolio patients dosed by mid 2027
- more than 2,000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.